A new immunotherapy approach could work for many types of cancer
Using new molecules that block an immune checkpoint, researchers showed they could stimulate a strong anti-tumor immune response.
Using new molecules that block an immune checkpoint, researchers showed they could stimulate a strong anti-tumor immune response.
A study profiling antigens presented on immune and tumor cells in co-culture points to new strategies for attacking a treatment-resistant and deadly brain cancer.
MIT researchers discover how an immune system molecule triggers neurons to shut down social behavior in mice modeling infection.
MIT researchers show they can use messenger RNA to activate the pathway and trigger the immune system to attack tumors.
Speakers at MIT’s Aging Brain Initiative symposium described how immune system factors during aging contribute to Alzheimer’s, Parkinson’s and other conditions. The field is leveraging that knowledge to develop new therapies.
The Fairbairn Menstruation Science Fund will allow researchers to accelerate the understanding and treatment of often-neglected diseases that tend to be more common in women.
CellLENS reveals hidden patterns in cell behavior within tissues, offering deeper insights into cell heterogeneity — vital for advancing cancer immunotherapy.
The BiophysicaL Immune Profiling for Infants (BLIPI) profiles an infant’s immune system in under 15 minutes, using just a single drop of blood.
The method could help predict whether immunotherapies will work in a patient or how a tumor will respond to drug treatment.
New research on a cytokine called IL-17 adds to growing evidence that immune molecules can influence behavior during illness.
Stefani Spranger is working to discover why some cancers don’t respond to immunotherapy, in hopes of making them more vulnerable to it.
In the United States and abroad, Matthew Dolan ’81 has served as a leader in immunology and virology.
When his son received a devastating diagnosis, Fernando Goldsztein MBA ’03 founded an initiative to help him and others.
The nanoparticle-based vaccine shows promise against many variants of SARS-CoV-2, as well as related sarbecoviruses that could jump to humans.
By examining antigen architectures, MIT researchers built a therapeutic cancer vaccine that may improve tumor response to immune checkpoint blockade treatments.